[Newly-developing therapies of pancreatic cancer--immunotherapy, gene therapy, differentiation therapy, endocrine therapy and others].
Pancreatic cancer is extremely resistant to various cancer therapies, however, variety of new therapies for pancreatic cancer have been investigated: (1) immunotherapy including cytokines like TNF, adoptive immunotherapy with lymphokine-activated killer cells or cytotoxic T-lymphocytes, and tumor vaccines using mutated Ki-ras oncoprotein or irradiated tumor cells which were transfected by cytokine genes; (2) gene therapy including transfer of cytokine genes or antisense Ki-ras oncogene, and a combination of gene transfer of herpes simplex virus thymidine kinase and subsequent administration of ganciclovir; (3) differentiation therapy including a quinolinone derivative, vesnarinone; (4) endocrine therapy including cholecystokinin-receptor antagonist, CR1505 or L364,718; (5) heavy water, and etc. All of these therapies will be applied for the treatment of pancreatic cancer in the near future.
Nio
Y
Y
First Department of Surgery, Shimane Medical University, Izumo, Japan.
Tamura
K
K
D000818:Animals; D001570:Benzodiazepinones / Q000627:therapeutic use; D017666:Deuterium Oxide / Q000627:therapeutic use; D020109:Devazepide; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy; D010190:Pancreatic Neoplasms / Q000628:therapy*; D011377:Proglumide / Q000031:analogs & derivatives / Q000627:therapeutic use; D015363:Quinolones / Q000627:therapeutic use; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors
D001570:Benzodiazepinones; D015363:Quinolones; D011949:Receptors, Cholecystokinin; C053737:loxiglumide; D011377:Proglumide; D017666:Deuterium Oxide; D020109:Devazepide